GE plans to invest €150m in a new biopharmaceutical manufacturing campus on Industrial Development Agency's site (IDA) at Loughbeg, Ringaskiddy, Co. Cork, Ireland.
GE BioPark Cork is subject to contract and planning approvals and will feature Europe’s first KUBio, a prefabricated, off-the-shelf bio-manufacturing facilities, owned and operated by GE customers.
This site will serve as focal point for further investment in next-generation Irish biopharmaceutical manufacturing.
Once the campus becomes fully operational, it is expected to provide more than 500 jobs, approximately 400 with biopharma companies and another 100 directly by GE.
GE healthcare life sciences CEO Kieran Murphy said: “Pharma companies worldwide are racing to respond to patient needs with new life-changing biological medicines and GE is investing in technology and service solutions, as well as industry skills and expertise, to enable them to make and get their products to market more quickly.
"We are delighted to be investing once again in Ireland, where we have ourselves a long history of manufacturing our own medical imaging products.”
Following the receipt of planning approvals, the construction phase is expected to begin by mid-2017 and create up to 800 construction jobs.
The project is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.
To develop biopharma manufacturing skills and expertise in Ireland, GE and the National Institute for Bioprocessing Research and Training (NIBRT) also plan to create a NIBRT-GE Single-use Centre of Excellence at NIBRT’s Dublin facility.
NIBRT intends to annually train up to 1,500 bioprocessing professionals on next-generation biologic manufacturing technologies, which will be used in GE BioPark Cork’s manufacturing facilities.
The GE-managed campus will include four fully equipped KUBio factories owned by independent biopharma companies manufacturing proprietary medicines, with GE operating centralised shared utilities and site services.
GE’s KUBio allows pharmaceutical companies to quickly deploy new biologics manufacturing capacity and enable medicines to reach the market faster.
Image: Graphical illustration of GE BioPark Cork. Photo: courtesy of Business Wire.